PTGX Fundamental Analysis - PROTAGONIST THERAPEUTICS INC

Fundamental Rating

Taking everything into account, PTGX scores 5 out of 10 in our fundamental rating. PTGX was compared to 540 industry peers in the Biotechnology industry. While PTGX has a great health rating, its profitability is only average at the moment. PTGX is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

PTGX had positive earnings in the past year.

PTGX had a positive operating cash flow in the past year.

PTGX had negative earnings in 4 of the past 5 years.

PTGX had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

With an excellent Return On Assets value of 7.25%, PTGX belongs to the best of the industry, outperforming 91.88% of the companies in the same industry.

PTGX has a better Return On Equity (7.79%) than 92.44% of its industry peers.

PTGX's Return On Invested Capital of 2.78% is amongst the best of the industry. PTGX outperforms 90.77% of its industry peers.

		Industry Rank	Sector Rank
ROA	7.25%
ROE	7.79%
ROIC	2.78%

ROA(3y)-12.16%

ROA(5y)-18.6%

ROE(3y)-13.93%

ROE(5y)-21.46%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

PTGX has a Profit Margin of 24.88%. This is amongst the best in the industry. PTGX outperforms 95.76% of its industry peers.

With an excellent Operating Margin value of 11.46%, PTGX belongs to the best of the industry, outperforming 92.62% of the companies in the same industry.

		Industry Rank	Sector Rank
OM	11.46%
PM (TTM)	24.88%
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PTGX is destroying value.

Compared to 1 year ago, PTGX has more shares outstanding

The number of shares outstanding for PTGX has been increased compared to 5 years ago.

PTGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

PTGX has an Altman-Z score of 44.55. This indicates that PTGX is financially healthy and has little risk of bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 44.55, PTGX belongs to the top of the industry, outperforming 97.60% of the companies in the same industry.

PTGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Altman-Z	44.55

ROIC/WACC0.29

WACC9.61%

2.3 Liquidity

A Current Ratio of 16.97 indicates that PTGX has no problem at all paying its short term obligations.

Looking at the Current ratio, with a value of 16.97, PTGX belongs to the top of the industry, outperforming 92.62% of the companies in the same industry.

PTGX has a Quick Ratio of 16.97. This indicates that PTGX is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of PTGX (16.97) is better than 92.62% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	16.97
Quick Ratio	16.97

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

PTGX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -73.28%.

The Revenue for PTGX has decreased by -34.45% in the past year. This is quite bad

PTGX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 352.10% yearly.

EPS 1Y (TTM)-73.28%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-10%

Revenue 1Y (TTM)-34.45%

Revenue growth 3Y151.34%

Revenue growth 5Y352.1%

Sales Q2Q%33.09%

3.2 Future

Based on estimates for the next years, PTGX will show a small growth in Earnings Per Share. The EPS will grow by 0.54% on average per year.

Based on estimates for the next years, PTGX will show a small growth in Revenue. The Revenue will grow by 7.60% on average per year.

EPS Next Y-148.06%

EPS Next 2Y-49.38%

EPS Next 3Y-31.39%

EPS Next 5Y0.54%

Revenue Next Year-85.73%

Revenue Next 2Y-29.52%

Revenue Next 3Y-14.56%

Revenue Next 5Y7.6%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 84.09, which means the current valuation is very expensive for PTGX.

90.59% of the companies in the same industry are more expensive than PTGX, based on the Price/Earnings ratio.

PTGX is valuated expensively when we compare the Price/Earnings ratio to 27.30, which is the current average of the S&P500 Index.

The Forward Price/Earnings Ratio is negative for PTGX. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	84.09
Fwd PE	N/A

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PTGX is valued cheaper than 89.67% of the companies in the same industry.

Based on the Price/Free Cash Flow ratio, PTGX is valued cheaply inside the industry as 91.88% of the companies are valued more expensively.

		Industry Rank	Sector Rank
P/FCF	98.7
EV/EBITDA	104.63

4.3 Compensation for Growth

A cheap valuation may be justified as PTGX's earnings are expected to decrease with -31.39% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-49.38%

EPS Next 3Y-31.39%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for PTGX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PROTAGONIST THERAPEUTICS INC

NASDAQ:PTGX (9/12/2025, 8:09:53 PM)

After market: 58.86 0 (0%)

58.86

-0.82 (-1.37%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-06 2025-08-06/amc

Earnings (Next)11-05 2025-11-05/amc

Inst Owners106.58%

Inst Owner Change6.34%

Ins Owners1.04%

Ins Owner Change-1.27%

Market Cap3.66B

Analysts84.44

Price Target70.75 (20.2%)

Short Float %10.44%

Short Ratio8.44

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)13.09%

Min EPS beat(2)6.78%

Max EPS beat(2)19.4%

EPS beat(4)4

Avg EPS beat(4)135.89%

Min EPS beat(4)6.78%

Max EPS beat(4)504.52%

EPS beat(8)8

Avg EPS beat(8)268.4%

EPS beat(12)10

Avg EPS beat(12)181.29%

EPS beat(16)13

Avg EPS beat(16)138.79%

Revenue beat(2)0

Avg Revenue beat(2)-14.45%

Min Revenue beat(2)-20.11%

Max Revenue beat(2)-8.8%

Revenue beat(4)2

Avg Revenue beat(4)81.15%

Min Revenue beat(4)-20.11%

Max Revenue beat(4)232.24%

Revenue beat(8)4

Avg Revenue beat(8)41.38%

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)1.06%

PT rev (3m)0.53%

EPS NQ rev (1m)-1.66%

EPS NQ rev (3m)-13.25%

EPS NY rev (1m)-1.83%

EPS NY rev (3m)-4.23%

Revenue NQ rev (1m)-20.57%

Revenue NQ rev (3m)-40.09%

Revenue NY rev (1m)-43.7%

Revenue NY rev (3m)-42.16%

Valuation

		Industry Rank	Sector Rank
PE	84.09
Fwd PE	N/A
P/S	17.5
P/FCF	98.7
P/OCF	92.6
P/B	5.48
P/tB	5.48
EV/EBITDA	104.63

EPS(TTM)0.7

EY1.19%

EPS(NY)-0.97

Fwd EYN/A

FCF(TTM)0.6

FCFY1.01%

OCF(TTM)0.64

OCFY1.08%

SpS3.36

BVpS10.74

TBVpS10.74

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	7.25%
ROE	7.79%
ROCE	3.51%
ROIC	2.78%
ROICexc	16.91%
ROICexgc	16.91%
OM	11.46%
PM (TTM)	24.88%
GM	N/A
FCFM	17.74%

ROA(3y)-12.16%

ROA(5y)-18.6%

ROE(3y)-13.93%

ROE(5y)-21.46%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0.29

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Debt/EBITDA	0
Cap/Depr	141.54%
Cap/Sales	1.17%
Interest Coverage	250
Cash Conversion	153.85%
Profit Quality	71.29%
Current Ratio	16.97
Quick Ratio	16.97
Altman-Z	44.55

F-Score4

WACC9.61%

ROIC/WACC0.29

Cap/Depr(3y)47.62%

Cap/Depr(5y)67.63%

Cap/Sales(3y)1.45%

Cap/Sales(5y)2%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-73.28%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-10%

EPS Next Y-148.06%

EPS Next 2Y-49.38%

EPS Next 3Y-31.39%

EPS Next 5Y0.54%

Revenue 1Y (TTM)-34.45%

Revenue growth 3Y151.34%

Revenue growth 5Y352.1%

Sales Q2Q%33.09%

Revenue Next Year-85.73%

Revenue Next 2Y-29.52%

Revenue Next 3Y-14.56%

Revenue Next 5Y7.6%

EBIT growth 1Y-84.25%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-195.33%

EBIT Next 3Y-30.57%

EBIT Next 5YN/A

FCF growth 1Y131.48%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y133.67%

OCF growth 3YN/A

OCF growth 5YN/A

PROTAGONIST THERAPEUTICS INC (PTGX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens